181 related articles for article (PubMed ID: 18234715)
21. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
[TBL] [Abstract][Full Text] [Related]
22. Infliximab: a review of its use in the management of rheumatoid arthritis.
Markham A; Lamb HM
Drugs; 2000 Jun; 59(6):1341-59. PubMed ID: 10882166
[TBL] [Abstract][Full Text] [Related]
23. Modern treatment strategies in rheumatoid arthritis.
Hetland ML
Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
[TBL] [Abstract][Full Text] [Related]
24. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
van Aken J; Heimans L; Gillet-van Dongen H; Visser K; Ronday HK; Speyer I; Peeters AJ; Huizinga TW; Allaart CF
Ann Rheum Dis; 2014 Feb; 73(2):396-400. PubMed ID: 23334213
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
26. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.
Stamm TA; Machold KP; Aletaha D; Alasti F; Lipsky P; Pisetsky D; Landewe R; van der Heijde D; Sepriano A; Aringer M; Boumpas D; Burmester G; Cutolo M; Ebner W; Graninger W; Huizinga T; Schett G; Schulze-Koops H; Tak PP; Martin-Mola E; Breedveld F; Smolen J
Arthritis Res Ther; 2018 Aug; 20(1):174. PubMed ID: 30092827
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
28. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.
Takeuchi T; Miyasaka N; Tatsuki Y; Yano T; Yoshinari T; Abe T; Koike T
Ann Rheum Dis; 2011 Jul; 70(7):1208-15. PubMed ID: 21478189
[TBL] [Abstract][Full Text] [Related]
29. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
30. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H
J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
[TBL] [Abstract][Full Text] [Related]
31. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
[TBL] [Abstract][Full Text] [Related]
32. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.
Klarenbeek NB; Güler-Yüksel M; van der Heijde DM; Hulsmans HM; Kerstens PJ; Molenaar TH; de Sonnaville PB; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2010 Dec; 69(12):2107-13. PubMed ID: 20610442
[TBL] [Abstract][Full Text] [Related]
33. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis.
Breedveld FC; Han C; Bala M; van der Heijde D; Baker D; Kavanaugh AF; Maini RN; Lipsky PE
Ann Rheum Dis; 2005 Jan; 64(1):52-5. PubMed ID: 15286005
[TBL] [Abstract][Full Text] [Related]
34. Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation.
Tam LS; Griffith JF; Yu AB; Li TK; Li EK
Clin Rheumatol; 2007 Jun; 26(6):941-6. PubMed ID: 16868816
[TBL] [Abstract][Full Text] [Related]
35. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M
Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
[TBL] [Abstract][Full Text] [Related]
39. Persistent low grade synovitis without erosive progression in magnetic resonance imaging of rheumatoid arthritis patients treated with infliximab over 1 year.
Fonseca JE; Canhão H; Tavares NJ; Cruz M; Branco J; Queiroz MV
Clin Rheumatol; 2009 Oct; 28(10):1213-6. PubMed ID: 19504146
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.
Kameda H; Sekiguchi N; Nagasawa H; Amano K; Takei H; Suzuki K; Nishi E; Ogawa H; Takeuchi T
Mod Rheumatol; 2006; 16(6):381-8. PubMed ID: 17165001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]